Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab
Carlos Guevara, Eduardo Villa, Marcela Cifuentes, Rodrigo Naves, José de Grazia
Topics & Concepts
AlemtuzumabNatalizumabMultiple sclerosisFingolimodMedicineCD52TeriflunomideGlatiramer acetateDaclizumabImmunologyLymphocyteDosingOcrelizumabRituximabInternal medicineMonoclonal antibodyAntibodyMultiple Sclerosis Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19